top of page

Yuexiu District 510080 Guangzhou,China

微信图片_20260506111713_39_3.jpg

Changjun Yin

Professor of Experimental Medicine 

Principal Investigator

Guest scientist in IPEK, LMU

📞 +86-020-87606870

📧 yinchj3@mail.sysu.edu.cn

🔗 www.yin-laboratory.com

I have been working on the topic of immune injury of chronic inflammatory diseases for more than 10 years and am fascinated by the hypothesis that tertiary lymphoid structures (TLSs) may organize disease-specific T-cell and B-cell responses under the pathological environments.  Understanding the underlying mechanisms and identification of the cognate antigens recognized by these disease-specific T-cells and B-cells are the major focus of our laboratory. We believed that these studies offer the unprecedented opportunity to understand how the immune system reacts to endogenous antigens, which are released during tissue injury under chronic inflammatory diseases, such as atherosclerosis, cancers, and Alzheimer's disease. Meanwhile, this new knowledge will lead to the next generation therapies for the benefit of patients suffering from these unresolvable diseases.

 

Key research achievements include the first report on the ApoE as a novel complement inhibitor protein to inhibit chronic inflammation in atherosclerosis and Alzheimer's disease (Nat Med, 2019), which leads to the new therapy using C5 siRNA to treat these diseases (US patent: US20210395735A1). We discovered the novel type of lipid pathology in human brains, named as “choroid plexus lipid deposition”, which may represent a novel hallmark pathology for Alzheimer's disease (Nat Med, 2019), this study highlights the lipid pathology may play key roles in the pathogenesis of AD. We uncovered that multiple T-cell tolerance checkpoint breakdown within atherosclerotic plaques may be the driving-force to promote atherosclerosis (Nature Cardiovascular Research, 2023). Our work on  TLSs in colorectal cancer liver metastasis in humans reported that TLS plasma cells secreted monoclonal antibodies can directly target tumor cells and prevent tumor growth (Cancer Cell, 2024), this represents a novel strategy to fight against cancers.

 

Training & Academic Career

2022 – present: Professor for Experimental Medicine, The First Affiliated Hospital, Sun Yat-sen University (SYSU), Guangzhou, China

2022 – present: Guest scientist, Institute for Cardiovascular Prevention (IPEK),

Ludwig-Maximilians-University (LMU) Munich, Germany

2018 – 2022: Group Leader/Immunity of Atherosclerosis-Brain Interfaces, IPEK, LMU, Munich, Germany

2014 – 2018: Postdoc training in Experimental Immunology, IPEK, LMU, Munich, Germany

2010 – 2013: PhD training in Experimental Immunology, Institute for Vascular Medicine(IVM)/Leibniz Institute on Aging (FLI), Jena, Germany

2003 – 2009: Bachelor and Maste of science training in molecular biology and biochemistry, College of Life Science & Technology at Huazhong Agricultural University, Wuhan, China

 

Awards & Honors

2019 Bayer Thrombosis Research Award 2019

Key Publications

sep..png
Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody−autoantigen pair in atherosclerosis 

Chuankai Zhang*, Xi Zhang*, Yi Ran*, Zhihua Wang*, Liping Li, Shu Wang, Junjie Zheng, Yixin Zhang, Ting Sun, Yutao Li, Shu Lu, Mingyang Hong, Zhe Ma, Sabine Steffens, Michael Hristov, Xavier Blanchet, Jingpu Zhu, Xinwen Dou, Xinyi Deng, Klaus Dornmair, Desheng Hu, Shibojyoti Lahiri, Axel Imhof, Nadja Sachs, Lars Maegdefessel, Jingyi Xiao, Jianning Zhang, Yan Wang, Hua Hong, Livia Habenicht, Xinyu Weng, Junbo Ge, Christian Weber, Donato Santovito, Rachael Bashford-Rogers, Sarajo K. Mohanta, Klaus Ley, Andreas J. R. Habenicht# & Changjun Yin#. Nature Cardiovascular Research (2026). PMID: 42706439; https://doi.org/10.1038/s44161-026-00864-w (*Shared First Authors; #Shared Corresponding Authors)

图片3.png

PD-1 blockade unleashes local hepatitis B virus-related B cell response inhibiting hepatocellular carcinoma

Shuling Chen#,*, Yuanqi Wang*, Jingying Chen*, Wenxuan Xie*, Jianyu Chen*, Guanrui Liao*, Xiaoxue Ren, Kai Lei, Yuting Zhang, Shu Wang, Ye Yang, Youmei Kang, Qiaoyi Chen, Yixi Wen, Jiaming Lai, Pengyuan Yang, Shunli Shen, Shaoqiang Li, Johnson Yiu-Nam Lau, Changjun Yin#, Ming Kuang#. Cancer Cell (2026). PMID: 42462708 DOI: 10.1016/j.ccell.2026.06.010 (*Shared First Authors; #Shared Corresponding Authors)

2_0.png
CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis

Yifan Zhang1,11* ∙ Guangjian Liu2,3,11*∙ Qianwen Zeng1,11*∙ Wenrui Wu4,11*∙ Kai Lei5,11*∙ Chuankai Zhang6,7,11*∙ Miaoling Tang7 ∙ Yuting Zhang8 ∙ Xiao Xiang1 ∙ Li Tan1 ∙ Rui Cui2,3 ∙ Si Qin2,3 ∙ Xinming Song5 ∙ Changjun Yin6,9,#∙ Zhihang Chen1,# ∙ Ming Kuang1,6,10,12,#; Cancer Cell 42, 1370-1385.e1379,doi: 10.1016/j.ccell.2024.07.006 (*Shared First Authors; #Shared Corresponding Authors )

微信图片_20260506111713_39_3.jpg

Changjun Yin

Professor of Experimental Medicine , Principal Investigator, Guest scientist in IPEK, LMU

📞 +86-020-87606870

I have been working on the topic of immune injury of chronic inflammatory diseases for more than 10 years and am fascinated by the hypothesis that tertiary lymphoid structures (TLSs) may organize disease-specific T-cell and B-cell responses under the pathological environments.  Understanding the underlying mechanisms and identification of the cognate antigens recognized by these disease-specific T-cells and B-cells are the major focus of our laboratory. We believed that these studies offer the unprecedented opportunity to understand how the immune system reacts to endogenous antigens, which are released during tissue injury under chronic inflammatory diseases, such as atherosclerosis, cancers, and Alzheimer's disease. Meanwhile, this new knowledge will lead to the next generation therapies for the benefit of patients suffering from these unresolvable diseases.

 

Key research achievements include the first report on the ApoE as a novel complement inhibitor protein to inhibit chronic inflammation in atherosclerosis and Alzheimer's disease (Nat Med, 2019), which leads to the new therapy using C5 siRNA to treat these diseases (US patent: US20210395735A1). We discovered the novel type of lipid pathology in human brains, named as “choroid plexus lipid deposition”, which may represent a novel hallmark pathology for Alzheimer's disease (Nat Med, 2019), this study highlights the lipid pathology may play key roles in the pathogenesis of AD. We uncovered that multiple T-cell tolerance checkpoint breakdown within atherosclerotic plaques may be the driving-force to promote atherosclerosis (Nature Cardiovascular Research, 2023). Our work on  TLSs in colorectal cancer liver metastasis in humans reported that TLS plasma cells secreted monoclonal antibodies can directly target tumor cells and prevent tumor growth (Cancer Cell, 2024), this represents a novel strategy to fight against cancers.

 

Training & Academic Career

2022 – present: Professor for Experimental Medicine, The First Affiliated Hospital, Sun Yat-sen University (SYSU), Guangzhou, China

2022 – present: Guest scientist, Institute for Cardiovascular Prevention (IPEK),

Ludwig-Maximilians-University (LMU) Munich, Germany

2018 – 2022: Group Leader/Immunity of Atherosclerosis-Brain Interfaces, IPEK, LMU, Munich, Germany

2014 – 2018: Postdoc training in Experimental Immunology, IPEK, LMU, Munich, Germany

2010 – 2013: PhD training in Experimental Immunology, Institute for Vascular Medicine(IVM)/Leibniz Institute on Aging (FLI), Jena, Germany

2003 – 2009: Bachelor and Maste of science training in molecular biology and biochemistry, College of Life Science & Technology at Huazhong Agricultural University, Wuhan, China

 

Awards & Honors

2019 Bayer Thrombosis Research Award 2019

CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis

 

Yifan Zhang1,11* ∙ Guangjian Liu2,3,11*∙ Qianwen Zeng1,11*∙ Wenrui Wu4,11*∙ Kai Lei5,11*∙ Chuankai Zhang6,7,11*∙ Miaoling Tang7 ∙ Yuting Zhang8 ∙ Xiao Xiang1 ∙ Li Tan1 ∙ Rui Cui2,3 ∙ Si Qin2,3 ∙ Xinming Song5 ∙ Changjun Yin6,9,#∙ Zhihang Chen1,# ∙ Ming Kuang1,6,10,12,#; Cancer Cell 42, 1370-1385.e1379,doi: 10.1016/j.ccell.2024.07.006 (*Shared First Authors; #Shared Corresponding Authors )

​

2_0.png
bottom of page